Clinical Complications

Polycystic Kidney Disease: Complications & Clinical Risks

Autosomal dominant polycystic kidney disease is the most common hereditary kidney disorder, causing progressive enlargement of fluid-filled cysts in the kidneys, hypertension, and eventual kidney failure. Tolvaptan slows kidney growth.

Overview of Major Complications

Renal and urological conditions generate complications through progressive nephron loss, impaired toxin clearance, hormonal disruption (erythropoietin, vitamin D, renin-angiotensin), and structural urological abnormalities. Chronic kidney disease is the central complication driver — each stage reduction in eGFR multiplies cardiovascular risk, anaemia burden, bone disease, and susceptibility to drug toxicity. Urological complications including obstruction and infection can precipitate acute kidney injury that accelerates chronic progression.

Early Complications

  • ⚠Acute kidney injury (AKI) — from dehydration, sepsis, contrast, or obstruction; may be reversible if treated promptly
  • ⚠Urinary tract infection — complicating structural abnormalities, reflux, catheter use, or immunosuppression
  • ⚠Haematuria — may indicate glomerulonephritis, bladder cancer, or urolithiasis; requires investigation
  • ⚠Hyperkalaemia — from kidney dysfunction; cardiac arrhythmia risk above 6.0 mmol/L
  • ⚠Fluid overload — from impaired renal excretion; peripheral oedema, pulmonary oedema
  • ⚠Anaemia — from reduced erythropoietin production in CKD; worsens cardiac strain

Long-Term Complications

  • →End-stage kidney disease — dialysis or transplantation dependence; eGFR <15 ml/min/1.73m²
  • →Cardiovascular disease — leading cause of death in CKD; 3–10× higher CV mortality vs. general population
  • →Renal anaemia — from EPO deficiency; fatigue, reduced exercise tolerance, cardiac hypertrophy
  • →Renal osteodystrophy — hyperparathyroidism, vitamin D deficiency, bone pain, fractures
  • →Metabolic acidosis — from reduced acid excretion; muscle wasting, bone loss, progression of CKD
  • →Uraemic encephalopathy — in advanced CKD; cognitive impairment, asterixis
  • →Malnutrition — protein-energy wasting in advanced CKD; mortality predictor
  • →Drug toxicity accumulation — renally-cleared drugs require dose adjustment; NSAIDs, contrast are nephrotoxic

Emergency Complications

Immediate clinical action required

  • ✕Hyperkalaemic cardiac arrest — tall T waves → VF; IV calcium gluconate, insulin-dextrose, kayexalate
  • ✕Pulmonary oedema from fluid overload — urgent dialysis if diuretics ineffective
  • ✕Urosepsis — from UTI with systemic compromise; IV antibiotics, source control (stent, nephrostomy)
  • ✕Complete urinary obstruction — acute obstructive uropathy; urgent decompression to preserve renal function
  • ✕Uraemic pericarditis — emergency dialysis required

What Increases Complication Risk

  • ↑Diabetes — most common cause of CKD and ESRD worldwide; nephropathy in >30% after 20 years
  • ↑Hypertension — second most common cause of CKD; poor BP control accelerates progression
  • ↑NSAID use — nephrotoxic; reduces renal perfusion; avoid in CKD
  • ↑Recurrent UTI with ascending infection — leads to pyelonephritis, scarring, and progressive CKD
  • ↑Obstruction — untreated hydronephrosis causes irreversible renal damage
  • ↑Contrast nephropathy — especially in pre-existing CKD and diabetes

What Reduces Complication Risk

  • ↓RAAS blockade (ACE inhibitor or ARB) — reduces proteinuria and slows CKD progression by 20–30%
  • ↓SGLT2 inhibitors — additional renoprotective benefit beyond glucose control in diabetic nephropathy
  • ↓BP control <130/80 mmHg — key modifiable target in CKD
  • ↓Avoidance of nephrotoxins: NSAIDs, contrast, aminoglycosides
  • ↓Regular eGFR and uACR monitoring — enables early detection of progressive nephropathy
  • ↓Dietary protein restriction and phosphate control in advanced CKD

When Urgent Reassessment is Needed

The following signs may indicate a new or worsening complication requiring prompt clinical evaluation:

  • ◆Acute oliguria or anuria — urgent exclusion of obstruction and AKI
  • ◆Serum potassium >6.0 mmol/L — urgent cardiac monitoring and treatment
  • ◆Sudden decrease in eGFR >25% from baseline — AKI investigation
  • ◆Severe oedema with breathlessness — fluid overload requiring urgent diuresis or dialysis
  • ◆Fever with loin pain — pyelonephritis; urosepsis if systemic compromise
  • ◆Haematuria with clot retention — urological emergency

Special Populations

Diabetics: earlier screening with uACR from diagnosis; SGLT2 inhibitors first-line in diabetic CKD
Elderly: reduced renal reserve; normal creatinine may mask significant CKD (use CKD-EPI formula); higher AKI risk with dehydration and NSAIDs
Transplant recipients: immunosuppression-related nephrotoxicity; calcineurin inhibitor levels critical
Children: congenital anomalies of kidney and urinary tract (CAKUT) require lifelong urological follow-up

Related Clinical Pages

Treatment & Management

Evidence-based treatment pathway, medications, and escalation criteria

Prognosis & Outlook

Long-term clinical outlook, improving and worsening outcome factors

Differential Diagnosis

Conditions that mimic Polycystic Kidney Disease — distinguishing features & tests

Polycystic Kidney Disease Overview

Symptoms, causes, and general condition overview

Similar Conditions With Different Risk Profiles

These conditions share overlapping symptoms with Polycystic Kidney Disease but have distinct complication patterns — understanding the differences is clinically important.

Chronic Kidney Disease (CKD) vs Polycystic Kidney DiseaseCompare →

Concerned about Polycystic Kidney Disease?

Describe your symptoms and get a structured clinical assessment — possible causes, red flags, and recommended next steps.

Start Free AI Analysis →

Medical References

Content on this page is informed by evidence-based clinical sources including: